Rid mousse
This article was originally published in The Tan Sheet
Executive Summary
Pfizer aerosol foam mousse lice treatment designated "approvable" in July 8 letter from FDA. Active ingredients are pyrethrins and piperonyl butoxide. Victoria, Australia-based Soltec Research, developer of a topical mousse delivery system, filed the original new drug application. Mousse formulation would join the Rid lice-control product line, which includes Maximum Strength Shampoo, Lice Control Spray, egg removal comb and Lice Egg Loosener Gel, which began shipping in mid-June (1"The Tan Sheet" June 21, p. 6)
You may also be interested in...
Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7. It is one of the first "NDA Deviations" to get the go-ahead from the agency; such an application is for a product that is comparable to products in a monograph but deviates in a significant way.
Pfizer
Rid Lice Egg Loosener Gel began shipping June 15. For use after lice-killing shampoo, the product "works safely and effectively to help dissolve the substance that glues the nit (egg) to the hair. And, it can help you meet your school's 'no-nit' policy with less effort so your child can get back to school fast," labeling says. The 2 oz. gel is available separately for about $8 at suggested retail and in the Rid Advanced Removal System, consisting of 2 oz. Maximum Strength Lice Killing Shampoo and 2 oz. Lice Egg Loosener, for around $14. Both products come with Pfizer's patented egg removal comb. Pfizer will include the new gel in consumer print, TV and professional ads and will add it to the brand's Web site (www.licerid.com)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC